慢性病性贫血

Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;2010:276-80.全文  摘要

Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014 Oct 16;124(16):2569-74.全文  摘要

Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46(7):678-84.全文  摘要

Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019 Apr 23;3(8):1197-1210.全文  摘要

Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct 1;29(suppl 4):iv271.全文  摘要

Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008 May;141(3):287-97. 摘要

1. Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;2010:276-80.全文  摘要

2. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood. 2002 Jul 15;100(2):474-82.全文  摘要

3. Niepel D, Klag T, Malek NP, et al. Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818769074.全文  摘要

4. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015 Mar;9(3):211-22.全文  摘要

5. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005 Nov;26(21):2232-7.全文  摘要

6. Markoulaki D, Kostikas K, Papatheodorou G, et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur J Intern Med. 2011 Feb;22(1):103-7.全文  摘要

7. Boutou AK, Pitsiou GG, Stanopoulos I, et al. Levels of inflammatory mediators in chronic obstructive pulmonary disease patients with anemia of chronic disease: a case-control study. QJM. 2012 Jul;105(7):657-63.全文  摘要

8. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004 Oct 15;104(8):2263-8.全文  摘要

9. Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996 Mar;55(3):162-8.全文  摘要

10. Van Iperen CE, van de Wiel A, Marx JJ. Acute event-related anaemia. Br J Haematol. 2001 Dec;115(4):739-43. 摘要

11. Walsh TS, Saleh EE, Lee RJ, et al. The prevalence and characteristics of anaemia at discharge home after intensive care. Intensive Care Med. 2006 Aug;32(8):1206-13. 摘要

12. Wong P, Intragumtornchai T. Hospital-acquired anemia. J Med Assoc Thai. 2006 Jan;89(1):63-7. 摘要

13. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011-23. 摘要

14. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989 Mar;3(5):1637-43. 摘要

15. Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol. 2010;2010:508739.全文  摘要

16. Spivak J. Iron and the anemia of chronic disease. Oncology (Williston Park). 2002 Sep;16(9 suppl 10):25-33. 摘要

17. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol. 2005 Mar;12(2):107-11. 摘要

18. Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1906-10.全文  摘要

19. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002 May 15;99(10):3505-16.全文  摘要

20. Ludwiczek S, Aigner E, Theurl I, et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003 May 15;101(10):4148-54.全文  摘要

21. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 May;113(9):1271-6.全文  摘要

22. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014 Oct 16;124(16):2569-74.全文  摘要

23. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46(7):678-84.全文  摘要

24. Taniguchi S, Dai CH, Price JO, et al. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood. 1997 Sep 15;90(6):2244-52.全文  摘要

25. Ganz T. Anemia of inflammation. N Engl J Med. 2019 Sep 19;381(12):1148-57. 摘要

26. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019 Jan 3;133(1):40-50.全文  摘要

27. Smith DL. Anemia in the elderly. Am Fam Physician. 2000 Oct 1;62(7):1565-72.全文  摘要

28. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693-9.全文  摘要

29. Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007 Aug;82(8):958-66. 摘要

30. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003 Oct;78(10):1274-80. 摘要

31. Elli L, Norsa L, Zullo A, et al. Diagnosis of chronic anaemia in gastrointestinal disorders: a guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). Dig Liver Dis. 2019 Apr;51(4):471-83. 摘要

32. Beutler E, Hoffbrand A, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program. 2003;40-61.全文  摘要

33. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011 Nov;86(11):923-7.全文  摘要

34. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997 Feb 1;89(3):1052-7.全文  摘要

35. Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26(1):1-9.全文  摘要

36. Nardone DA, Roth KM, Mazur DJ, et al. Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med. 1990 Jan;150(1):201-4. 摘要

37. Gjorup T, Bugge PM, Hendriksen C, et al. A critical evaluation of the clinical diagnosis of anemia. Am J Epidemiol. 1986 Oct;124(4):657-65. 摘要

38. Hung OL, Kwon NS, Cole AE, et al. Evaluation of the physician's ability to recognize the presence or absence of anemia, fever, and jaundice. Acad Emerg Med. 2000 Feb;7(2):146-56.全文  摘要

39. Sheth TN, Choudhry NK, Bowes M, et al. The relation of conjunctival pallor to the presence of anemia. J Gen Intern Med. 1997 Feb;12(2):102-6.全文  摘要

40. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994 Aug 15;84(4):997-1004. 摘要

41. Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med. 1990 Aug;89(2):161-8. 摘要

42. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med. 1992 Nov 1;117(9):739-48. 摘要

43. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994 Aug 15;84(4):1056-63. 摘要

44. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002 May 15;20(10):2486-94. 摘要

45. Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis. 2018;2018:9394060.全文  摘要

46. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141-7.全文  摘要

47. Corrado A, Di Bello V, d'Onofrio F, et al. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis. Int J Immunopathol Pharmacol. 2017 Sep;30(3):302-7.全文  摘要

48. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279-335.全文

49. O'Lone EL, Hodson EM, Nistor I, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2019;2(2):CD007857.全文  摘要

50. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis. 1999 May-Jun;5(3):346-52.全文  摘要

51. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019 Apr 23;3(8):1197-1210.全文  摘要

52. National Institute for Health and Care Excellence. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy. November 2014 [internet publication].全文

53. Canadian Agency for Drugs and Technologies in Health. Overview of systematic review and economic evaluation of erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy. April 2009 [internet publication].全文

54. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70. 摘要

55. Crathorne L, Huxley N, Haasova M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess. 2016 Feb;20(13):1-588. 摘要

56. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008 Aug 12;179(4):333-7.全文  摘要

57. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic growth factors [internet publication].全文

58. Qaseem A, Humphrey LL, Fitterman N, et al. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013 Dec 3;159(11):770-9.全文  摘要

59. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.全文  摘要

60. Blau CA. Erythropoietin in cancer: presumption of innocence? Stem Cells. 2007 Aug;25(8):2094-7.全文  摘要

61. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19;102(2):301-15.全文  摘要

62. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009 Jun 10;27(17):2838-47.全文  摘要

63. Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016 Feb 4;(2):CD009624.全文  摘要

64. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008 Dec;6(3-4):93-102.全文  摘要

65. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008 Nov;52(5):897-906. 摘要

66. Littlewood TJ, Alikhan R. The use of intravenous iron in patients with cancer-related anaemia. Br J Haematol. 2008 Jun;141(6):751-6. 摘要

67. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010;2010:338-47.全文  摘要

68. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016 Jan;91(1):31-8.全文  摘要

69. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct 1;29(suppl 4):iv271.全文  摘要

70. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990 Mar 3;300(6724):573-8.全文  摘要

71. Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev. 2016 Jan 20;(1):CD003266.全文  摘要

72. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006 May;47(5 suppl 3):S11-145.全文  摘要

73. Leyland-Jones B, Bondarenko I, Nemsadze G, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016 Apr 10;34(11):1197-207. 摘要

74. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009 Jun;45(9):1603-15.全文  摘要

75. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008 May;141(3):287-97. 摘要

76. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007 Feb 3;369(9559):381-8. 摘要

77. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc. 2007 Nov;82(11):1371-80. 摘要

78. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007 Sep 6;357(10):965-76.全文  摘要

79. Hebert PC, Fergusson DA. Can erythropoietin eradicate red cell transfusions in the critically ill? Crit Care Med. 2006 Sep;34(9):2490-1. 摘要

80. Katsarou A, Pantopoulos K. Hepcidin therapeutics. Pharmaceuticals (Basel). 2018 Nov 21;11(4):127.全文  摘要

81. Schmid H, Schiffl H, Lederer SR. New strategies for managing anemia of chronic kidney disease. Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):339-51. 摘要

82. Kamioner D. Erythropoietin biosimilars currently available in hematology-oncology. Target Oncol. 2012 Mar;7(suppl 1):S25-8. 摘要

83. Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother. 2012 Mar;13(4):495-503. 摘要

84. Debeljak N, Sytkowski AJ. Erythropoietin and erythropoiesis stimulating agents. Drug Test Anal. 2012 Nov;4(11):805-12. 摘要

85. Gertz B, Kes P, Essaian A, et al. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin. 2012 Jul;28(7):1101-10.全文  摘要

86. Saglimbene VM, Palmer SC, Ruospo M, et al. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2017 Aug 7;(8):CD009904.全文  摘要

87. Hahn D, Esezobor CI, Elserafy N, et al. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev. 2017 Jan 9;(1):CD011690.全文  摘要

88. Bacchetta J, Zaritsky JJ, Lisse TS, et al. Vitamin D as a new regulator of iron metabolism: vitamin D suppresses hepcidin in vitro and in vivo. Nephrol Dial Transplant. 2012;27(suppl 2):ii28-30.

89. Perlstein TS, Pande R, Berliner N, et al. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011 Mar 10;117(10):2800-6. 摘要

90. Kumar VA, Kujubu DA, Sim JJ, et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011 Jan-Feb;24(1):98-105. 摘要

91. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010 Nov 4;116(18):3627-34. 摘要

92. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford). 2012 May;51(5):852-7.全文  摘要

93. Hoffman R, Benz EJ Jr, Shattil SJ, et al. eds. Hematology: basics, principles, and practice. 4th ed. Philadelphia, PA: Elsevier; 2005.